ICLR
ICON PLC
$151.82
-0.28%
$11.7B
No data for this timeframe.
Vol
Market Cap$11.7B
Cap SizeLarge Cap
Analyst ConsensusBuy (58%)
SEC Reports3
Congressional2 trades
Exchange Nasdaq·Sector Services-Commercial Physical & Biological Research·CIK 0001060955·Prev Close $152.24
Recent Activity
Jun 6, 2026
earnings_calendar
ICLR Q4 2025 Earnings After Market Close — 2026-06-06
May 27, 2026
SEC
ICON plc filed Q4/FY2025 results alongside the conclusion of an Audit Committee investigation that found revenue oversta
6-K — Impact 8/10
May 27, 2026
SEC
ICON plc filed its FY2025 20-F, which restates FY2023 and FY2024 financials due to an Audit Committee investigation that
20-F — Impact 8/10
May 26, 2026
SEC
ICON plc disclosed receipt of a Nasdaq deficiency notice due to the delayed filing of its Form 20-F for FY2025, and anno
6-K — Impact 6/10
May 14, 2026
Insider
Murphy Ronan Martin sold 5,005 shares
Director @ $0.00 ($0.00)
May 14, 2026
Insider
McCague Eugene Pacelli sold 3,255 shares
Director @ $0.00 ($0.00)
May 14, 2026
Insider
McCague Eugene Pacelli sold 3,255 shares
Director @ $0.00 ($0.00)
Mar 5, 2026
Congress
Kevin Hern sell
$100,001 - $250,000 — House
Price Targets
$153.25
+0.9% upside
Hold
Current $151.82
Low $125.00
Median $155.00
High $180.00
16 analysts
$125.00
$180.00
Analyst Ratings
5Strong Buy
9Buy
9Hold
1Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 1, 2026 | TD Cowen | MAINTAIN | Buy → Buy |
| Jun 1, 2026 | B of A Securities | MAINTAIN | Underperform → Underperform |
| May 29, 2026 | Citigroup | MAINTAIN | Neutral → Neutral |
| May 29, 2026 | Truist Securities | MAINTAIN | Hold → Hold |
| May 29, 2026 | RBC Capital | MAINTAIN | Sector Perform → Sector Perform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $2.43 ▼ -15.1% | $2.29 — $2.55 | -24% YoY | 13 |
| Next Q | $2.55 ▼ -12.5% | $2.42 — $2.63 | -22% YoY | 13 |
| Current FY | $10.54 ▼ -10.9% | $10.25 — $10.84 | -16% YoY | 17 |
| Next FY | $11.70 ▼ -8.5% | $11.11 — $12.68 | 11% YoY | 17 |
Latest Reports
BEARISH
6-K
8/10
ICON plc filed Q4/FY2025 results alongside the conclusion of an Audit Committee investigation that found revenue oversta
May 27, 2026
BEARISH
20-F
8/10
ICON plc filed its FY2025 20-F, which restates FY2023 and FY2024 financials due to an Audit Committee investigation that
May 27, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 14, 2026 | Murphy Ronan | A | $0.00 |
| May 14, 2026 | McCague Eugene | D | $0.00 |
| May 14, 2026 | McCague Eugene | A | $0.00 |
| May 14, 2026 | CLIMAX JOHN | D | $0.00 |
| May 14, 2026 | CLIMAX JOHN | A | $0.00 |
Congressional Trades
2 members: 0 buys, 2 sells
| Member | Party | Type | Amount |
|---|---|---|---|
| Kevin Hern | R | SELL | $100,001 - $250,000 |
| Julia Letlow | R | SELL | $1,001 - $15,000 |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
3 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 14, 2026 | Murphy Ronan Martin | Director | A | 5,005 | $0.00 | $0.00 |
| May 14, 2026 | McCague Eugene Pacelli | Director | D | 3,255 | $0.00 | $0.00 |
| May 14, 2026 | McCague Eugene Pacelli | Director | A | 3,255 | $0.00 | $0.00 |
| May 14, 2026 | CLIMAX JOHN DR | Director | D | 5,005 | $0.00 | $0.00 |
| May 14, 2026 | CLIMAX JOHN DR | Director | A | 5,005 | $0.00 | $0.00 |
| May 14, 2026 | Murphy Ronan Martin | Director | D | 5,005 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 3 bearish, 0 mixed, 0 neutral. Avg impact: 7.3/10.
BEARISH
6-K
8/10
ICON plc filed Q4/FY2025 results alongside the conclusion of an Audit Committee investigation that f
May 27, 2026
BEARISH
20-F
8/10
ICON plc filed its FY2025 20-F, which restates FY2023 and FY2024 financials due to an Audit Committe
May 27, 2026
BEARISH
6-K
6/10
ICON plc disclosed receipt of a Nasdaq deficiency notice due to the delayed filing of its Form 20-F
May 26, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Hold (58% buy). Based on 24 analysts: 5 strong buy, 9 buy, 9 hold, 1 sell, 0 strong sell.
Analyst Price Targets
$153.25 mean target
+0.9% upside
Hold (2.12)
$125.00 Low
$180.00 High
| Metric | Value |
|---|---|
| Current Price | $151.82 |
| Target Low | $125.00 |
| Target Mean | $153.25 |
| Target Median | $155.00 |
| Target High | $180.00 |
| # Analysts | 16 |
| Recommendation | Hold (2.12) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$2.43 | $2.29 | $2.55 | -23.8% | -15.1% | 0↑ 8↓ | $2.0B | 0.1% | 13 |
| Next Q 2026-06-30 |
$2.55 | $2.42 | $2.63 | -21.8% | -12.5% | 1↑ 6↓ | $2.0B | -1.1% | 13 |
| Current FY 2026-12-31 |
$10.54 | $10.25 | $10.84 | -15.9% | -10.9% | 3↑ 12↓ | $8.0B | -2.8% | 17 |
| Next FY 2027-12-31 |
$11.70 | $11.11 | $12.68 | 11.0% | -8.5% | 2↑ 9↓ | $8.2B | 2.5% | 17 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $2.430 | |
| 7d ago | $2.736 | -0.306 |
| 30d ago | $2.863 | -0.433 |
| 60d ago | $3.073 | -0.643 |
| 90d ago | $3.093 | -0.663 |
9 analyst firms have rated this stock: 3 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 1, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| Jun 1, 2026 | B of A Securities | MAINTAIN | Underperform | Underperform |
| May 29, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| May 29, 2026 | Truist Securities | MAINTAIN | Hold | Hold |
| May 29, 2026 | RBC Capital | MAINTAIN | Sector Perform | Sector Perform |
| May 29, 2026 | JP Morgan | MAINTAIN | Neutral | Neutral |
| May 29, 2026 | Barclays | MAINTAIN | Equal-Weight | Equal-Weight |
| May 29, 2026 | BMO Capital | MAINTAIN | Outperform | Outperform |
| May 18, 2026 | JP Morgan | MAINTAIN | Neutral | Neutral |
| Mar 26, 2026 | BMO Capital | UPGRADE | Market Perform | Outperform |
| Mar 11, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Mar 9, 2026 | Barclays | MAINTAIN | Equal-Weight | Equal-Weight |
| Feb 23, 2026 | Jefferies | UPGRADE | Hold | Buy |
| Feb 18, 2026 | TD Cowen | UPGRADE | Hold | Buy |
| Jan 22, 2026 | TD Cowen | MAINTAIN | Hold | Hold |
| Jan 8, 2026 | Truist Securities | DOWNGRADE | Buy | Hold |
| Dec 15, 2025 | Barclays | MAINTAIN | Equal-Weight | Equal-Weight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 9 | 9 | 1 | 0 | 58% | |
| May 1, 2026 | 5 | 8 | 9 | 1 | 0 | 57% | |
| Apr 1, 2026 | 5 | 9 | 9 | 1 | 0 | 58% | |
| Mar 1, 2026 | 5 | 8 | 10 | 1 | 0 | 54% | |
| Feb 1, 2026 | 4 | 9 | 11 | 0 | 0 | 54% | |
| Jan 1, 2026 | 4 | 10 | 10 | 0 | 0 | 58% |
Strong BuyBuyHoldSellStrong Sell
2 members of Congress traded this stock: 0 buys, 2 sells.
Congressional Trades
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | Kevin Hern | R | HOUSE | SELL | $100,001 - $250,000 | Icon PLC | Apr 6, 2026 (33d) |
| Feb 12, 2026 | Julia Letlow | R | HOUSE | SELL | $1,001 - $15,000 | Icon PLC | Mar 13, 2026 (30d) |
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 9, 2026
Clinical Trial
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss
Phase Phase 3 — COMPLETED
Jun 6, 2026
earnings_calendar
ICLR Q4 2025 Earnings After Market Close — 2026-06-06
Jun 5, 2026
short_volume
Short Volume: ICLR — 59.6% short (0.4M / 0.6M)
Short: 367,150 | Exempt: 39 | TRF Vol: 615,920 | Short Ratio: 59.6% | Off-exchange volume (dark pool + OTC)
Jun 4, 2026
short_volume
Short Volume: ICLR — 56.1% short (0.4M / 0.8M)
Short: 441,566 | Exempt: 55 | TRF Vol: 786,552 | Short Ratio: 56.1% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
short_volume
Short Volume: ICLR — 71.5% short (0.4M / 0.6M)
Short: 420,253 | Exempt: 1 | TRF Vol: 587,771 | Short Ratio: 71.5% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
earnings_calendar
ICLR Q1 2026 Earnings After Market Close — 2026-06-02
May 26, 2026
earnings_calendar
ICLR Q1 2026 Earnings After Market Close — 2026-05-26
May 23, 2026
Clinical Trial
Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
Phase Phase 2 — COMPLETED
May 22, 2026
clinical_trial_readout
Results Pending: JTT-861 Capsules (Phase 2) — Completed 4d ago
Trial: Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
Sponsor: Akros Pharma Inc.
May 14, 2026
short_volume
Short Volume: ICLR — 78.5% short (0.4M / 0.5M)
Short: 407,690 | Exempt: 0 | TRF Vol: 519,392 | Short Ratio: 78.5% | Off-exchange volume (dark pool + OTC)
May 6, 2026
short_volume
Short Volume: ICLR — 61.8% short (0.3M / 0.5M)
Short: 337,000 | Exempt: 0 | TRF Vol: 545,602 | Short Ratio: 61.8% | Off-exchange volume (dark pool + OTC)
May 5, 2026
short_volume
Short Volume: ICLR — 56.3% short (0.5M / 0.9M)
Short: 483,800 | Exempt: 0 | TRF Vol: 859,479 | Short Ratio: 56.3% | Off-exchange volume (dark pool + OTC)
May 1, 2026
earnings_calendar
ICLR Q1 2026 Earnings After Market Close — 2026-05-01
Apr 30, 2026
short_volume
Short Volume: ICLR — 66.0% short (0.5M / 0.7M)
Short: 460,452 | Exempt: 0 | TRF Vol: 698,168 | Short Ratio: 66.0% | Off-exchange volume (dark pool + OTC)
Apr 30, 2026
earnings_calendar
ICLR Q4 2025 Earnings After Market Close — 2026-04-30
Apr 29, 2026
earnings_calendar
ICLR Q1 2026 Earnings After Market Close — 2026-04-29
Apr 17, 2026
short_interest
FTD: ICLR — 14,000 shares ($1.6M) failed to deliver
Settlement: 20260417, Price: $115.58, FTD Value: $1,618,120, ICON PLC ADR